DOCK2: A Novel FLT3/ITD Leukemia Drug Target

Oncotarget - United States
doi 10.18632/oncotarget.21390
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

8-Chloro-Adenosine Activity in FLT3-ITD Acute Myeloid Leukemia

Journal of Cellular Physiology
Clinical BiochemistryCell BiologyPhysiology
2019English

DNA Damage on the DOCK in FLT3-ITD-driven Acute Myeloid Leukemia

Haematologica
Hematology
2019English

Targeting BTK for the Treatment of FLT3-ITD Mutated Acute Myeloid Leukemia

Scientific Reports
Multidisciplinary
2015English

NPMc+ Cooperates With Flt3/Itd Mutations to Cause Acute Leukemia Recapitulating Human Disease

Experimental Hematology
Cancer ResearchGeneticsHematologyMolecular BiologyCell Biology
2014English

Tyrosine Kinase Inhibition Increases the Cell Surface Localization of FLT3-ITD and Enhances FLT3-directed Immunotherapy of Acute Myeloid Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2017English

The Clinical Significance of FLT3 ITD Mutation on the Prognosis of Adult Acute Promyelocytic Leukemia

Hematology
Hematology
2017English

A Novel Predictive Model of Outcome in Acute Myeloid Leukemia Without Favorable Karyotype Based on Treatment Strategy, Karyotype and FLT3-ITD Mutational Status

American Journal of Hematology
Hematology
2018English

Overcoming AC220 Resistance of FLT3-ITD by SAR302503

Blood Cancer Journal
OncologyHematology
2013English

Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells Through Increased McL-1 Proteasomal Degradation

Clinical Cancer Research
Cancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy